Last Updated: November 8, 2026

Patent: 11,629,187

Summary for Patent: 11,629,187

Title:	Checkpoint blockade and microsatellite instability
Abstract:	Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
Inventor(s):	Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
Assignee:	Johns Hopkins University
Application Number:	US17/354,656
Patent Claims:	see list of patent claims

Details for Patent 11,629,187

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	11,629,187	2041-06-22
Msd International Business Gmbh	KEYTRUDA	pembrolizumab	For Injection	125514	September 4, 2014	11,629,187	2041-06-22
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	11,629,187	2041-06-22
Msd International Business Gmbh	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	11,629,187	2041-06-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,629,187

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2015346295	⤷ Start Trial
Australia	2019201671	⤷ Start Trial
Australia	2021202086	⤷ Start Trial
Canada	2966660	⤷ Start Trial
China	106999582	⤷ Start Trial
China	113694193	⤷ Start Trial
European Patent Office	3218004	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.